Epilepsy research
-
Multicenter Study Clinical Trial
Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy.
Patients with juvenile myoclonic epilepsy (JME) may be resistant or show adverse effects to valproate. We present a multicenter, prospective, long-term, open-label study evaluating the efficacy and safety of levetiracetam in JME. ⋯ This open-label study suggests levetiracetam may be effective and well tolerated in resistant cases of JME or may become a reasonable alternative to valproate in newly diagnosed patients.